FLT3 and acute myeloid leukemia: Having been recently integrated into frontline AML trials [162,163,164], the combination of venetoclax plus FLT3 inhibition is currently undergoing evaluation in multiple clinical trials for the treatment of FLT3-mutated AML [165,166,167].